RT Journal Article
SR Electronic
T1 Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.20.20178772
DO 10.1101/2020.08.20.20178772
A1 Andrew Ip
A1 Jaeil Ahn
A1 Yizhao Zhou
A1 Andre H. Goy
A1 Eric Hansen
A1 Andrew L Pecora
A1 Brittany A Sinclaire
A1 Urszula Bednarz
A1 Michael Marafelias
A1 Shivam Mathura
A1 Ihor S Sawczuk
A1 Joseph P. Underwood
A1 David M. Walker
A1 Rajiv Prasad
A1 Robert L. Sweeney
A1 Marie G. Ponce
A1 Samuel La Capra
A1 Frank J. Cunningham
A1 Arthur G. Calise
A1 Bradley L. Pulver
A1 Dominic Ruocco
A1 Greggory E. Mojares
A1 Michael P. Eagan
A1 Kristy L. Ziontz
A1 Paul Mastrokyriakos
A1 Stuart L Goldberg
YR 2020
UL http://medrxiv.org/content/early/2020/08/25/2020.08.20.20178772.abstract
AB Background Hydroxychloroquine has not been associated with improved survival among hospitalized COVID-19 patients in the majority of observational studies and similarly was not identified as an effective prophylaxis following exposure in a prospective randomized trial. We aimed to explore the role of hydroxychloroquine therapy in mildly symptomatic patients diagnosed in the outpatient setting.Methods We examined the association between outpatient hydroxychloroquine exposure and the subsequent progression of disease among mildly symptomatic non-hospitalized patients with documented SARS-CoV-2 infection. The primary outcome assessed was requirement of hospitalization. Data was obtained from a retrospective review of electronic health records within a New Jersey USA multi-hospital network. We compared outcomes in patients who received hydroxychloroquine with those who did not applying a multivariable logistic model with propensity matching.Results Among 1274 outpatients with documented SARS-CoV-2 infection 7.6% were prescribed hydroxychloroquine. In a 1067 patient propensity matched cohort, 21.6% with outpatient exposure to hydroxychloroquine were hospitalized, and 31.4% without exposure were hospitalized. In the primary multivariable logistic regression analysis with propensity matching there was an association between exposure to hydroxychloroquine and a decreased rate of hospitalization from COVID-19 (OR 0.53; 95% CI, 0.29, 0.95). Sensitivity analyses revealed similar associations. QTc prolongation events occurred in 2% of patients prescribed hydroxychloroquine with no reported arrhythmia events among those with data available.Conclusions In this retrospective observational study of SARS-CoV-2 infected non-hospitalized patients hydroxychloroquine exposure was associated with a decreased rate of subsequent hospitalization. Additional exploration of hydroxychloroquine in this mildly symptomatic outpatient population is warranted.Lay Summary In this observational study of 1,274 COVID-19 patients, hydroxychloroquine given as an outpatient treatment was associated with a 47% reduction in the hazard of hospitalization. Adverse events were not increased (2% QTc prolongation events, 0% arrhythmias). Further validation is required. Use of hydroxychloroquine to treat COVID-19 in the outpatient setting should be reserved for a clinical trial or after discussion with a physician regarding risks and benefits.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted work; AHG reports being a study investigator for Genentech-Hoffman La Roche, during the conduct of the study; research funding as study investigator from Acerta, AstraZeneca, Celgene, Kite Pharma, Elsevier's PracticeUpdate Oncology, Gilead, Medscape, MJH Associates, OncLive Peer Exchange, Physicians Education Resource, and Xcenda, outside the submitted work, and research funding as a study investigator for Constellation, Infinity, Infinity Verastem, Janssen, Karyopharm, and Pharmacyclics, outside of the submitted work. EH and SM report consulting for Regional Cancer Care Associates and Hackensack Meridian Health, outside the submitted work. ALP and SLG report having equity ownership in COTA, outside the submitted work. No other relationships or activities that could appear to have influenced the submitted work.Clinical TrialNCT04347993Funding StatementNo external funding was received to support this research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Hackensack Meridian Health IRB approved this study under #Pro2020-0342. The following waivers were approved for this study: Waiver of consent, and Waiver of HIPAA authorization.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified Data may be requested directly from Hackensack Meridian Health. Please contact the corresponding author, Dr. Stuart Goldberg, for specific inquiries.